Skip to main content

Drug Interactions between Detectnet and pasireotide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

pasireotide copper cu 64 dotatate

Applies to: pasireotide and Detectnet (copper Cu 64 dotatate)

ADJUST DOSING INTERVAL: Coadministration of copper Cu 64 dotatate with non-radioactive somatostatin analogs may diminish the diagnostic effects of copper Cu 64 dotatate positron emission tomography (PET) imaging. Somatostatin analogs competitively bind to the same somatostatin receptor as copper Cu 64 dotatate, which may prevent the uptake of copper Cu 64 dotatate into tissues and affect the diagnostic imaging results.

MANAGEMENT: PET imaging with copper Cu 64 dotatate should be performed prior to dosing with somatostatin analogs. For patients receiving short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging. For patients receiving long-acting somatostatin analogs, a washout period of 28 days is recommended prior to imaging.

References (1)
  1. (2020) "Product Information. Detectnet (copper cu 64 dotatate)." Currax Pharmaceuticals LLC

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer